KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Fulgent Genetics (FLGT) over the last 11 years, with Q3 2025 value amounting to $1.2 billion.

  • Fulgent Genetics' Liabilities and Shareholders Equity fell 155.62% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 billion, marking a year-over-year decrease of 184.75%. This contributed to the annual value of $1.2 billion for FY2024, which is 124.37% down from last year.
  • As of Q3 2025, Fulgent Genetics' Liabilities and Shareholders Equity stood at $1.2 billion, which was down 155.62% from $1.2 billion recorded in Q2 2025.
  • Fulgent Genetics' 5-year Liabilities and Shareholders Equity high stood at $1.5 billion for Q1 2022, and its period low was $999.1 million during Q1 2021.
  • Over the past 5 years, Fulgent Genetics' median Liabilities and Shareholders Equity value was $1.2 billion (recorded in 2024), while the average stood at $1.3 billion.
  • In the last 5 years, Fulgent Genetics' Liabilities and Shareholders Equity soared by 101848.08% in 2021 and then plummeted by 1087.44% in 2023.
  • Over the past 5 years, Fulgent Genetics' Liabilities and Shareholders Equity (Quarter) stood at $1.3 billion in 2021, then rose by 8.39% to $1.4 billion in 2022, then dropped by 10.87% to $1.2 billion in 2023, then decreased by 1.24% to $1.2 billion in 2024, then fell by 0.44% to $1.2 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.2 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.2 billion for Q1 2025.